These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2009375)

  • 1. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group.
    Carey PJ; Proctor SJ; Taylor P; Hamilton PJ
    Blood; 1991 Apr; 77(7):1593-8. PubMed ID: 2009375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.
    Jackson GH; Lennard AL; Taylor PR; Carey P; Angus B; Lucraft H; Evans RG; Proctor SJ
    Br J Cancer; 1994 Sep; 70(3):501-5. PubMed ID: 7521662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
    Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
    Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up.
    Mehta J; Powles R; Treleaven J; Horton C; Shepherd V; Hale G; Waldmann H; Singhal S
    Leuk Lymphoma; 1997 May; 25(5-6):479-86. PubMed ID: 9250818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.
    Freedman AS; Takvorian T; Neuberg D; Mauch P; Rabinowe SN; Anderson KC; Soiffer RJ; Spector N; Grossbard M; Robertson MJ
    J Clin Oncol; 1993 May; 11(5):931-6. PubMed ID: 8487057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
    Phillips GL; Shepherd JD; Barnett MJ; Lansdorp PM; Klingemann HG; Spinelli JJ; Nevill TJ; Chan KW; Reece DE
    J Clin Oncol; 1991 Oct; 9(10):1880-8. PubMed ID: 1919638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
    Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
    Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.
    Mehta J; Powles R; Singhal S; Horton C; Tait D; Treleaven J
    Bone Marrow Transplant; 1996 Jul; 18(1):119-23. PubMed ID: 8832004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous bone marrow transplantation in childhood acute lymphoid leukemia with use of purging.
    Billett AL; Sallan SE
    Am J Pediatr Hematol Oncol; 1993 May; 15(2):162-8. PubMed ID: 8498641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: the European Bone Marrow Transplant Group experience. EBMT Working Party for Lymphoma.
    Schouten HC; Colombat P; Verdonck LF; Gorin NC; Björkstrand B; Taghipour G; Goldstone AH
    Ann Oncol; 1994; 5 Suppl 2():147-9. PubMed ID: 8204514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
    Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
    Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma.
    Prince HM; Crump M; Imrie K; Stewart AK; Girouard C; Brandwein JM; Carstairs K; Pantalony D; Scott G; Sutcliffe S; Sutton DM; Tsang R; Keating A
    Ann Oncol; 1996 Dec; 7(10):1043-9. PubMed ID: 9037363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplantation Group.
    Bonetti F; Zecca M; Pession A; Messina C; Montagna D; Lanino E; Fagioli F; Santoro N; Prete A; Cesaro S; Rondelli R; Giorgiani G; De Stefano P; Locatelli F
    J Clin Oncol; 1999 Dec; 17(12):3729-35. PubMed ID: 10577844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation.
    McCowage GB; Vowels MR; Shaw PJ; Lockwood L; Mameghan H
    J Clin Oncol; 1995 Nov; 13(11):2789-95. PubMed ID: 7595740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.
    Prince HM; Imrie K; Crump M; Stewart AK; Girouard C; Colwill R; Brandwein J; Tsang RW; Scott JG; Sutton DM; Pantalony D; Carstairs K; Sutcliffe SB; Keating A
    Br J Haematol; 1996 Mar; 92(4):880-9. PubMed ID: 8616081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation.
    Philip T; Chauvin F; Armitage J; Bron D; Hagenbeek A; Biron P; Spitzer G; Velasquez W; Weisenburger DD; Fernandez-Ranada J
    Blood; 1991 Apr; 77(7):1587-92. PubMed ID: 2009374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission - long-term follow-up.
    Vaidya SJ; Atra A; Bahl S; Pinkerton CR; Calvagna V; Horton C; Milan S; Shepherd V; Brain C; Treleaven J; Powles R; Tait D; Meller ST
    Bone Marrow Transplant; 2000 Mar; 25(6):599-603. PubMed ID: 10734293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia.
    Tiley C; Powles R; Treleaven J; Catovsky D; Milan S; Teo CP; Catalano J; Mehta J; Shields M; Gupta P
    Bone Marrow Transplant; 1993 Nov; 12(5):449-55. PubMed ID: 8298555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up.
    Vose JM; Bierman PJ; Anderson JR; Kessinger A; Pierson J; Nelson J; Frappier B; Schmit-Pokorny K; Weisenburger DD; Armitage JO
    Blood; 1992 Oct; 80(8):2142-8. PubMed ID: 1356515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.